CareDx to Report Second Quarter 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers - today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please visit the investor relations section of CareDx's website at: investors.caredxinc.com.

About CareDx - The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.